Mark Joinnides - Vaxxinity Chief Staff
| VAXXDelisted Stock | USD 2.72 0.19 6.53% |
Insider
Mark Joinnides is Chief Staff of Vaxxinity
| Phone | 254 244 5739 |
| Web | https://www.vaxxinity.com |
Vaxxinity Management Efficiency
The company has return on total asset (ROA) of (0.4834) % which means that it has lost $0.4834 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5065) %, meaning that it created substantial loss on money invested by shareholders. Vaxxinity's management efficiency ratios could be used to measure how well Vaxxinity manages its routine affairs as well as how well it operates its assets and liabilities.Vaxxinity currently holds 15.17 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Vaxxinity has a current ratio of 5.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vaxxinity until it has trouble settling it off, either with new capital or with free cash flow. So, Vaxxinity's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vaxxinity sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vaxxinity to invest in growth at high rates of return. When we think about Vaxxinity's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Eliem Therapeutics | 63 | |
| Sonia DPHIL | PepGen | 38 | |
| Amy Conrad | Tyra Biosciences | N/A | |
| Noah MD | Travere Therapeutics | 57 | |
| Edward MD | Third Harmonic Bio | 51 | |
| James JD | Eliem Therapeutics | 58 | |
| Gregg Keaney | Third Harmonic Bio | N/A | |
| Adam Hansard | Applied Therapeutics | 47 | |
| MSc MBA | Passage Bio | 55 | |
| Wei MD | Erasca Inc | 54 | |
| Muhammad AlHajj | IO Biotech | 53 | |
| Anders Ljungqvist | IO Biotech | N/A | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| Conor Richardson | Shattuck Labs | N/A | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Simona King | Passage Bio | 52 | |
| David MD | Passage Bio | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| Allison Talbot | PureTech Health PLC | N/A | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Peter Heerma | Travere Therapeutics | 52 | |
Management Performance
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.48 |
Vaxxinity Leadership Team
Elected by the shareholders, the Vaxxinity's board of directors comprises two types of representatives: Vaxxinity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaxxinity. The board's role is to monitor Vaxxinity's management team and ensure that shareholders' interests are well served. Vaxxinity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaxxinity's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Louis IV, CoFounder Chairman | ||
| Peter MD, Global VP | ||
| Jon Harrison, Chief Officer | ||
| Mei JD, CEO Director | ||
| Ulo MD, Chief Officer | ||
| Benjamin Matone, VP Relations | ||
| Mark Joinnides, Chief Staff | ||
| Sumita JD, Chief Officer | ||
| Dario MD, Senior Diseases | ||
| Dwayne Soisson, VP Operations | ||
| Rene Molina, G Sec | ||
| Mark MSE, Chief Staff | ||
| MBA MS, Chief Officer | ||
| JeanCosme Dodart, Senior Research |
Vaxxinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Vaxxinity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | (1.39 M) | ||||
| Shares Outstanding | 112.91 M | ||||
| Shares Owned By Insiders | 50.90 % | ||||
| Shares Owned By Institutions | 12.24 % | ||||
| Number Of Shares Shorted | 4.22 M | ||||
| Price To Book | 4.58 X | ||||
| Price To Sales | 4,605 X | ||||
| Gross Profit | (1.87 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Vaxxinity Pink Sheet
If you are still planning to invest in Vaxxinity check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaxxinity's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world |